These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 8779105)

  • 1. [The therapeutic and diagnostic potentials of the intra-corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction].
    Mzo EB; Dmitriev DG
    Ter Arkh; 1995; 67(10):45-8. PubMed ID: 8779105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intracavernous injection test by prostaglandin E1].
    Otani T
    Nihon Rinsho; 2002 Jun; 60 Suppl 6():173-7. PubMed ID: 12166133
    [No Abstract]   [Full Text] [Related]  

  • 3. Cavernous auto-injection therapy with prostaglandin E1.
    Nisén H
    Ann Chir Gynaecol Suppl; 1993; 206():69-73. PubMed ID: 8291874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intracavernous injection of prostaglandin E1 as a diagnostic test in erectile dysfunction].
    Marín Lafuente JC; Sańchez Moreno Horencia M; Puy Figuero Echeverría M; Llarena Ibarguren R; Pertusa Peña C
    Arch Esp Urol; 1990; 43(6):661-3. PubMed ID: 2092621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intracavernous injections of prostaglandin E1 in the treatment of erection disorders].
    Beretta G; Zanollo A; Portalupi W
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):481-5. PubMed ID: 1838836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
    Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
    Polito M; d'Anzeo G; Conti A; Muzzonigro G
    BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
    Bratus D; Hlebic G; Hajdinjak T
    Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intracavernous auto-injection of prostaglandin E1 for diagnosis and treatment of erectile dysfunction].
    Arielly J; Weinberg D; Eliraz A; Adam M; el-Hanani BI; Eisenkraft S
    Harefuah; 1994 Apr; 126(7):369-73, 426. PubMed ID: 8200581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
    Elhanbly S; Schoor R; Elmogy M; Ross L; Hegazy A; Niederberger C
    J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The intracavernous injection of Edex (prostaglandin E1) in the treatment of erectile impotence in persons in older age groups].
    Gorilovskiĭ LM
    Urol Nefrol (Mosk); 1996; (6):31-3. PubMed ID: 9036606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
    Shabsigh R; Padma-Nathan H; Gittleman M; McMurray J; Kaufman J; Goldstein I
    Urology; 2000 Apr; 55(4):477-80. PubMed ID: 10736486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial experiences with prostaglandin E1 and PGE1 prepared injections].
    Mattarelli G; Leibundgut B
    Helv Chir Acta; 1991 Sep; 58(3):335-7. PubMed ID: 1769856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
    Chen RN; Lakin MM; Montague DK; Ausmundson S
    J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin E1 in the therapy of erectile deficiency.
    Beretta G; Zanollo A; Ascani L; Re B
    Acta Eur Fertil; 1989; 20(5):305-8. PubMed ID: 2636808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of prostaglandin El in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction].
    Porst H
    Urologe A; 1988 Jan; 27(1):22-6. PubMed ID: 3284144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.